AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32502243 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intake of phosphorus and calcium
Number of subjects: 20
Study 36163662 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based care (1-week hospitalisation)
Number of subjects: 425
Study 36163662 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care (2 months hospitalisation)
Number of subjects: 425
Study 34273973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 1 + FUN program
Number of subjects: 171
Study 34273973 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 171
Study 35643173 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe device
Number of subjects: 1359
Study 35643173 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 1359
Study 35643173 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe arm
Number of subjects: 1359
Study 34531712 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (diet and physical activity)
Number of subjects: 1641
Study 32187075 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents (women and URM members)
Number of subjects: 927
Study 32187075 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents (women)
Number of subjects: 927
Study 32187075 — intervention group
Group type: COMPARATOR
Intervention: Survey respondents (men)
Number of subjects: 927
Study 32187075 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents
Number of subjects: 927
Study 35074433 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-guided DP-IMRT
Number of subjects: 260
Study 33465274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Program (CRP), nine-week course starting day 40±5 post-AuSCT
Number of subjects: 32
Study 33465274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Program (CRP)
Number of subjects: 32
Study 35820656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookstove intervention
Number of subjects: 230
Study 34892575 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially Distributed Sequential Stimulation (SDSS)
Number of subjects: 1
Study 34892575 — intervention group
Group type: COMPARATOR
Intervention: Constant Frequency Trains (CFTs) at 30Hz
Number of subjects: 1
Study 34892575 — intervention group
Group type: COMPARATOR
Intervention: Constant Frequency Trains (CFTs) at 40Hz
Number of subjects: 1
Study 34892575 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet Frequency Trains (DFTs)
Number of subjects: 1
Study 33535924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level training group
Number of subjects: 175
Study 33535924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level training group
Number of subjects: 175
Study 33535924 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 33074695 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantaged group (received more resources)
Number of subjects: 176
Study 33074695 — intervention group
Group type: COMPARATOR
Intervention: Disadvantaged group (received fewer resources)
Number of subjects: 176
Study 33074695 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantaged children over time
Number of subjects: 176
Study 33074695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (advantaged and disadvantaged)
Number of subjects: 176
Study 36114990 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL-1601D
Number of subjects: 478
Study 36114990 — intervention group
Group type: COMPARATOR
Intervention: Ref-InsAsp-US
Number of subjects: 478
Study 33693678 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of any majority DRM
Number of subjects: 178
Study 33693678 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of any majority DRM with <2 active drugs
Number of subjects: 178
Study 33693678 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minority variants (MVs) alone
Number of subjects: 178
Study 33693678 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of pre-ART MVs with majority DRMs
Number of subjects: 178
Study 32901239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberglass 'Figaro' crowns
Number of subjects: 10
Study 32901239 — intervention group
Group type: COMPARATOR
Intervention: Preformed metal crowns (PMCs)
Number of subjects: 10
Study 36155982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT scans
Number of subjects: 93
Study 36155982 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT scans
Number of subjects: 93
Study 36155982 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CT scans
Number of subjects: 93
Study 35597983 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Dutch Workplace Health Promotion Program (WHPP) for 12 months
Number of subjects: 0
Study 35597983 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32822354 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling services (Group S)
Number of subjects: 105
Study 32822354 — intervention group
Group type: COMPARATOR
Intervention: No counseling experience (Group H)
Number of subjects: 105
Study 33820636 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol (4°C)
Number of subjects: 90
Study 33820636 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution (4°C)
Number of subjects: 90
Study 32678879 — intervention group
Group type: EXPERIMENTAL
Intervention: RT alone (arm A)
Number of subjects: 36
Study 32678879 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with concomitant and adjuvant TMZ (arm B)
Number of subjects: 36
Study 32678879 — intervention group
Group type: COMPARATOR
Intervention: TMZ alone (arm C)
Number of subjects: 36
Study 32678879 — intervention group
Group type: EXPERIMENTAL
Intervention: RT arms (pooled arms A + B)
Number of subjects: 36
Study 32413673 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 120
Study 32413673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32413673 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat polymorphism of the androgen receptor gene
Number of subjects: 120
Study 35969885 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.45 mg/d
Number of subjects: 45
Study 35969885 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 mg/d (patch replaced weekly)
Number of subjects: 45
Study 35969885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 45
Study 33629110 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg every 4 weeks
Number of subjects: 0
Study 33629110 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg every 4 weeks
Number of subjects: 0
Study 33629110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32952837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugary food consumption (once or more times per day)
Number of subjects: 226
Study 32952837 — intervention group
Group type: EXPERIMENTAL
Intervention: Good oral hygiene status
Number of subjects: 226
Study 33764241 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% rebamipide
Number of subjects: 38
Study 33764241 — intervention group
Group type: COMPARATOR
Intervention: 0.03% tacrolimus ointment
Number of subjects: 38
Study 33764241 — intervention group
Group type: COMPARATOR
Intervention: 0.05% cyclosporine
Number of subjects: 38
Study 34909101 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/NPPV
Number of subjects: 255
Study 34909101 — intervention group
Group type: COMPARATOR
Intervention: HFNC
Number of subjects: 255
Study 32594453 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (L) therapy at a final dose of 3.0 mg/day
Number of subjects: 72
Study 32594453 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (L) therapy
Number of subjects: 72
Study 34932102 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg RSVpreF
Number of subjects: 618
Study 34932102 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 µg RSVpreF
Number of subjects: 618
Study 34932102 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 µg RSVpreF
Number of subjects: 618
Study 34932102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 34932102 — intervention group
Group type: EXPERIMENTAL
Intervention: All RSVpreF formulations
Number of subjects: 618
Study 33689118 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle family‐based intervention
Number of subjects: 280
Study 33689118 — intervention group
Group type: COMPARATOR
Intervention: Control condition (referral to community services)
Number of subjects: 280
Study 32366207 — intervention group
Group type: EXPERIMENTAL
Intervention: Brains Ahead! Intervention
Number of subjects: 60
Study 35555179 — intervention group
Group type: EXPERIMENTAL
Intervention: NED (Novel Energy Drink)
Number of subjects: 45
Study 32202333 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 164
Study 32202333 — intervention group
Group type: COMPARATOR
Intervention: Non smokers
Number of subjects: 164
Study 35320289 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship prospective audit and feedback (PAF) plus standard of care (SOC)
Number of subjects: 530
Study 35320289 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 530
Study 32056983 — intervention group
Group type: COMPARATOR
Intervention: Outdoor aerobic training (40-min running, 4 days/week for 18 weeks)
Number of subjects: 32
Study 32056983 — intervention group
Group type: COMPARATOR
Intervention: Indoor aerobic training (40-min running, 4 days/week for 18 weeks)
Number of subjects: 32
Study 34962176 — intervention group
Group type: EXPERIMENTAL
Intervention: Film therapy analysis (12 sessions, one session per week)
Number of subjects: 30
Study 34962176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 32939557 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant diet (30% animal protein, 70% plant protein)
Number of subjects: 136
Study 32939557 — intervention group
Group type: COMPARATOR
Intervention: Animal diet (70% animal protein, 30% plant protein)
Number of subjects: 136
Study 32939557 — intervention group
Group type: COMPARATOR
Intervention: 50/50 diet (50% animal protein, 50% plant protein)
Number of subjects: 136
Study 32962710 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced imaging follow-up protocol (radiographs at week 6 and 12 on clinical indication)
Number of subjects: 246
Study 32962710 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine radiography at weeks 6 and 12)
Number of subjects: 246
Study 35866010 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care noninterruptive clinical decision support delivering the 5-year kidney failure risk equation and recommendations for monitoring and referral.
Number of subjects: 5590
Study 35866010 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 5590
Study 34731132 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 60
Study 34731132 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 33769014 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-PNL
Number of subjects: 245
Study 33769014 — intervention group
Group type: COMPARATOR
Intervention: standard-PNL
Number of subjects: 245
Study 33769014 — intervention group
Group type: EXPERIMENTAL
Intervention: PNL-Trifecta achievement
Number of subjects: 245
Study 33769014 — intervention group
Group type: EXPERIMENTAL
Intervention: length of stay
Number of subjects: 245
Study 34684442 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored therapy (n = 54; with an option of dose modification)
Number of subjects: 109
Study 34684442 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 55; 500 IU vitamin D standard therapy)
Number of subjects: 109
Study 35202942 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans Affairs Brief Intervention and Contact Program (VA BIC)
Number of subjects: 20
Study 35202942 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 34350728 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum iodide (Q1)
Number of subjects: 448
Study 34350728 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum iodide (Q4)
Number of subjects: 448
Study 34350728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroglobulin (Tg)
Number of subjects: 448
Study 34350728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone (TSH)
Number of subjects: 448
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab
Number of subjects: 1185
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 1185
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: Early VA response at Week 4
Number of subjects: 1185
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: Early VA response at Week 12
Number of subjects: 1185
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: VA response at Week 4 and 12
Number of subjects: 1185
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: VA response prediction
Number of subjects: 1185
Study 616117379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining VA responses at Week 4 and 12
Number of subjects: 1185
Study 32323015 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mm lumen apposing metal stent (LAMS)
Number of subjects: 105
Study 34294114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine 1–2 mg/h from the day before surgery until the fifth postoperative day and standard of care
Number of subjects: 336
Study 34294114 — intervention group
Group type: COMPARATOR
Intervention: Surgery only and standard of care
Number of subjects: 336
Study 34514682 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 3379
Study 34514682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3379
Study 34648011 — intervention group
Group type: EXPERIMENTAL
Intervention: HuCare Quality Improvement Strategy
Number of subjects: 762
Study 34648011 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 762
Study 32074268 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (intravenous ertapenem 1 g once daily for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Number of subjects: 530
Study 32074268 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendectomy
Number of subjects: 530
Study 32074268 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (with subsequent appendectomy)
Number of subjects: 530
Study 32074268 — intervention group
Group type: COMPARATOR
Intervention: Successful antibiotic therapy
Number of subjects: 530
Study 34549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced high-intensity exercise
Number of subjects: 98
Study 34549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced moderate-intensity exercise
Number of subjects: 98
Study 34549700 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 98
Study 32939898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment at weeks 0, 12, 24, 36, and 48.
Number of subjects: 787
Study 32939898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity assessment at weeks 0, 12, 24, 36, and 48.
Number of subjects: 787
Study 32939898 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the number of pain sites at weeks 0, 12, 24, 36, and 48.
Number of subjects: 787
Study 32939898 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level pain variability analysis over 48 weeks.
Number of subjects: 787
Study 616594938 — intervention group
Group type: EXPERIMENTAL
Intervention: ROOTS intervention
Number of subjects: 29
Study 616594938 — intervention group
Group type: COMPARATOR
Intervention: Control (standard district practices)
Number of subjects: 29
Study 34325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020
Study 34325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020
Study 34325887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 34325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 34325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype group 1
Number of subjects: 7020
Study 34325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype group 2
Number of subjects: 7020
Study 34325887 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype group 3
Number of subjects: 7020
Study 32417345 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 Gy in 6 fractions, twice a week (arm 1)
Number of subjects: 34
Study 32417345 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy in 16 fractions, four times a week (arm 2)
Number of subjects: 34
Study 616651858 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a injected subcutaneously three times weekly (IFN beta-1a SC tiw)
Number of subjects: 0
Study 616651858 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a injected intramuscularly once weekly (IFN beta-1a IM qw)
Number of subjects: 0
Study 616651858 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a IM qw
Number of subjects: 0
Study 616651858 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a SC tiw
Number of subjects: 0
Study 34353237 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative simulated voices
Number of subjects: 346
Study 34353237 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral simulated voices
Number of subjects: 346
Study 34353237 — intervention group
Group type: COMPARATOR
Intervention: Ambient sound (control)
Number of subjects: 346
Study 33285623 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT; n=12)
Number of subjects: 36
Study 33285623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Physical Rehabilitation (CPR; n=12)
Number of subjects: 36
Study 33285623 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training Exercises (Control; n=12)
Number of subjects: 36
Study 32243407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 108
Study 32243407 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (OHAs)
Number of subjects: 108
Study 32506992 — intervention group
Group type: EXPERIMENTAL
Intervention: EG1 - Treatment group designed to change sexual scripts for consensual sex
Number of subjects: 324
Study 32506992 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 - Treatment group designed to promote sexual self-esteem and challenge perceived realism of pornography
Number of subjects: 324
Study 32506992 — intervention group
Group type: COMPARATOR
Intervention: CG - Non-treatment control group
Number of subjects: 324
Study 33863854 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with machines
Number of subjects: 43
Study 33863854 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with elastic tubes
Number of subjects: 43
Study 33863854 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 33863854 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (8 weeks after training)
Number of subjects: 43
Study 34949604 — intervention group
Group type: EXPERIMENTAL
Intervention: Codesigned care transition support including patient information using videos, leaflets, teach back, what-matters-to-me dialogue, coordinated rehabilitation plan, bridged e-meeting, and message system for cross-organisational collaboration.
Number of subjects: 0
Study 34949604 — intervention group
Group type: COMPARATOR
Intervention: Matched controls from other geriatric stroke and acute stroke units, and matched historic controls from a previous dataset at the intervention and control units.
Number of subjects: 0
Study 32000816 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal cocktail injection
Number of subjects: 0
Study 35405714 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS v2.0
Number of subjects: 202
Study 35405714 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS v2.1
Number of subjects: 202
Study 33264546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (chemoprevention group)
Number of subjects: 1049
Study 33264546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1049
Study 34724323 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized microinjections of tranexamic acid (4 mg/ml) plus Q-switched 1064 laser every 2 weeks
Number of subjects: 40
Study 34724323 — intervention group
Group type: COMPARATOR
Intervention: Oral tranexamic acid 250 mg three times a day plus Q-switched 1064 laser every 2 weeks
Number of subjects: 40
Study 34724323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 32910831 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 at 1 mL/kg/h (group 1)
Number of subjects: 24
Study 32910831 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 at 2 mL/kg/h (group 2)
Number of subjects: 24
Study 32910831 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 24
Study 35610125 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BaS)
Number of subjects: 2300845
Study 35610125 — intervention group
Group type: COMPARATOR
Intervention: Control (no bariatric surgery)
Number of subjects: 2300845
Study 33403921 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-focused digital meditation training
Number of subjects: 0
Study 33403921 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 32792268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage with tap water (G2)
Number of subjects: 22
Study 32792268 — intervention group
Group type: COMPARATOR
Intervention: No lavage (G1)
Number of subjects: 22
Study 34974959 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromandibular approach
Number of subjects: 21